Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy
Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.
Top-30
Journals
|
1
2
3
|
|
|
International Immunopharmacology
3 publications, 4.62%
|
|
|
Molecular Pharmaceutics
3 publications, 4.62%
|
|
|
Frontiers in Immunology
3 publications, 4.62%
|
|
|
Nature Communications
2 publications, 3.08%
|
|
|
International Journal of Biological Macromolecules
2 publications, 3.08%
|
|
|
International Journal of Pharmaceutics
2 publications, 3.08%
|
|
|
International Journal of Molecular Sciences
2 publications, 3.08%
|
|
|
Cells
1 publication, 1.54%
|
|
|
Colloids and Surfaces A: Physicochemical and Engineering Aspects
1 publication, 1.54%
|
|
|
Journal of Controlled Release
1 publication, 1.54%
|
|
|
Applied Biochemistry and Biotechnology
1 publication, 1.54%
|
|
|
Journal of Cancer Research and Clinical Oncology
1 publication, 1.54%
|
|
|
Process Biochemistry
1 publication, 1.54%
|
|
|
Applied Physics Reviews
1 publication, 1.54%
|
|
|
Cancers
1 publication, 1.54%
|
|
|
ImmunoHorizons
1 publication, 1.54%
|
|
|
Journal of Drug Delivery Science and Technology
1 publication, 1.54%
|
|
|
Life
1 publication, 1.54%
|
|
|
Cell Death Discovery
1 publication, 1.54%
|
|
|
Antibody Therapeutics
1 publication, 1.54%
|
|
|
Molecules
1 publication, 1.54%
|
|
|
Journal of Biological Engineering
1 publication, 1.54%
|
|
|
Journal of Pharmaceutical Analysis
1 publication, 1.54%
|
|
|
Biochemical Pharmacology
1 publication, 1.54%
|
|
|
Current Protein and Peptide Science
1 publication, 1.54%
|
|
|
Molecular Therapy
1 publication, 1.54%
|
|
|
Scientific Reports
1 publication, 1.54%
|
|
|
Pharmaceutics
1 publication, 1.54%
|
|
|
Journal of Immunological Methods
1 publication, 1.54%
|
|
|
1
2
3
|
Publishers
|
5
10
15
20
25
|
|
|
Elsevier
21 publications, 32.31%
|
|
|
Springer Nature
14 publications, 21.54%
|
|
|
MDPI
8 publications, 12.31%
|
|
|
American Chemical Society (ACS)
6 publications, 9.23%
|
|
|
Frontiers Media S.A.
4 publications, 6.15%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 3.08%
|
|
|
AIP Publishing
1 publication, 1.54%
|
|
|
The American Association of Immunologists
1 publication, 1.54%
|
|
|
Oxford University Press
1 publication, 1.54%
|
|
|
Research Square Platform LLC
1 publication, 1.54%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 1.54%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 1.54%
|
|
|
Taylor & Francis
1 publication, 1.54%
|
|
|
Public Library of Science (PLoS)
1 publication, 1.54%
|
|
|
Pleiades Publishing
1 publication, 1.54%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.